EQGen Biomedical - Building the Next Generation of Veterinary Medicine
A global veterinary biotechnology company founded to advance innovative medicines
EQGen Biomedical is developing an off-the-shelf, allogeneic cell-therapy platform designed to address the underlying biology of veterinary musculoskeletal disease. Our lead program applies proprietary integrin α10β1 cell-selection technology to isolate and purify a defined population of multipotent mesenchymal stem cells for the treatment of equine inflammatory and degenerative joint disease. The product is being advanced for equine osteoarthritis with the objective of becoming a true Disease-Modifying Osteoarthritis Drug (DMOAD), while establishing a broader regenerative medicine platform with potential applications across additional veterinary species and musculoskeletal indications.
Moving beyond symptom management
Current treatment approaches primarily focus on reducing pain and inflammation. EQGen is pursuing a different objective: developing a biologic therapy with the potential to modify disease progression and support long-term joint health. As a targeted therapy being developed toward FDA approval and European marketing authorization, EQGen’s product has the potential to modify the underlying joint disease and represent a meaningful advance in veterinary medicine.
Our mission is to deliver next-generation products in veterinary medicine and to optimize the health of animals globally.
The burden of joint disease
Osteoarthritis (OA) is a leading cause of equine lameness. As in humans, OA is a chronic degenerative disease involving the entire joint. Because articular cartilage has limited capacity for intrinsic repair, osteoarthritis-related cartilage damage can become progressive and difficult to reverse. The result is painful joints with crepitation, decreased range of motion and loss of performance.
Current clinical management targets symptomatic pain relief and reduction of joint inflammation. Commonly used medications and existing autologous and allogeneic treatments primarily address pain and inflammation and generally provide limited regenerative benefit.
EQGen Biomedical is developing a standardized, off-the-shelf, cost-effective allogeneic stem cell therapy that eliminates the need for patient-specific blood or tissue collection and requires no product preparation before administration. Its proprietary selection process is designed to produce a more defined and consistent mesenchymal stem cell population than conventional, unselected MSC approaches. Unlike therapies focused primarily on symptom management, EQGen’s product is being engineered as a true disease-modifying treatment with the potential to address the underlying biology of osteoarthritis, preserve joint structure, support cartilage repair, and reverse the course of disease progression.
Our experienced leadership team brings proven expertise in developing and commercializing regenerative medicine products for equine and companion-animal use. The team combines leadership experience from Wyeth, Eli Lilly, Pfizer, Merck Animal Health, and commercial-stage regenerative medicine companies whose products have been used in more than 40,000 horses and dogs to date.